Valneva SE, a specialty vaccine company, and Instituto Butantan, producer of immunobiologic products is preparing to start Phase 3 clinical studies of a single-shot chikungunya vaccine, VLA1553, in the United States later this year.
Thailand ended 2019 with 11,484 chikungunya cases, more than triple the 3,580 cases reported in 2018.
This year, the city recorded 37,973 cases of chikungunya between January and November. In the same period last year, the government recorded 9,545 cases.
Indonesia saw a 76% drop in dengue infections in the part of Indonesia where the mosquitoes were released. In Brazil, treated neighborhoods in Rio de Janeiro saw rates of dengue infections fall by 70%, and infections with chikungunya was 75% lower. North Queensland, Australia, hasn’t had a dengue in five years, and there has been a 96% reduction in locally acquired dengue infections.
The Republic of the Congo chikungunya epidemic that began in January has grown to 8,000 cases, affecting eight departments.
Thailand health officials reported an additional 500-plus chikungunya cases during the past week, bringing the outbreak total, primarily in the south, to 2,551 cases.
The chikungunya outbreak that began last year in southern Thailand continues into the first month of 2019 as country health officials report more than 1,000 cases through January 28.
Researchers identified space-time clusters of dengue, chikungunya, and Zika, to understand the dynamics and interaction between these simultaneously circulating arboviruses in a densely populated and heterogeneous city.
Valneva VLA1553 was shown to be highly immunogenic in vaccinated Non-Human Primates and showed no signs of viremia after challenge.
A study performed at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungunya virus and yellow fever virus.